← All trials
NCT06334497
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2024
- Primary completion
- Sep 30, 2027
- Completion date
- Nov 30, 2027
- First posted
- Mar 28, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Assistance Publique - Hôpitaux de ParisOfficial
- Assistance Publique - Hôpitaux de ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.